biotech semaglutide Novo Nordisk said on Tuesday its triple agonist UBT251 of the receptors for GLP-1, GIP and glucagon, jointly developed with United Biotechnology, achieved a statistically significant mean weight loss of up to Novo Nordisk Wegovy, Medicare Advantage:

These results make it a very different tool from older weight loss medications like phentermine

Submission for the use of the drug to treat type 2 diabetes is expected next year.

R.FerrisJ

But in my two decades of studying the neuroscience behind what motivates us to eat and take drugs, and the ways they may overlap, these weight-loss medicines are also the most promising option Ive seen for a drug that could treat addiction, whether to alcohol, opioids, or nicotine

However, many medical professionals recommend slowly tapering off to avoid a rapid increase in hunger and reduce the risk of weight regain

WangSOestrickerLZWallendorfMJSterlKDunaiJKilpatrickCRet al